Studies suggest Tirzepatide is a pharmacological agent that may act as an agonist of the GLP-1 receptor. Researchers speculate the agent may emulate the actions of the hormone GLP-1, thereby enhancing glycemic regulation and inducing weight reduction [i].
Tirzepatide has been subjected to rigorous scientific investigation, including animal reproductive studies and trials, and has been speculated to be productive. Tirzepatide has suggested favorable outcomes in regulating glucose levels and inducing substantial weight reduction. [ii].
Tirzepatide Peptide Mechanism of Action
Studies suggest Tirzepatide may exert its potential through dual mechanisms of action:
As a GLP-1 receptor agonist, this substance is suggested by research to emulate the physiological actions of the hormone GLP-1. Scientists speculate Tirzepatide may exert its action by binding to glucagon-like peptide-1 (GLP-1) receptors, potentially activating them and eliciting comparable physiological responses as GLP-1. The endogenous hormone GLP-1 may elicit insulin secretion from the pancreas, suppresses hepatic glucose output, and retard intestinal glucose absorption. This leads to a decrease in glycemia and enhanced insulin sensitivity.
Research suggests Tirzepatide may exhibit dual activity on the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP). A gastric inhibitory polypeptide (GIP) may induce pancreatic insulin secretion and adipose tissue accumulation, whereas Tirzepatide has been speculated to mitigate the actions of GIP to facilitate weight reduction.
Licensed professionals speculate Tirzepatide may enhance glycemic control, induce weight loss, and enhance insulin sensitivity by stimulating GLP-1 receptors and inhibiting the possible actions of GIP. Studies have suggested the potential and efficacy of presenting Tirzepatide to animal test subjects.
Tirzepatide Peptide Properties
Research studies and guidelines have suggested the properties of Tirzepatide mentioned below:
- Studies suggest Tirzepatide may significantly reduce blood glucose levels, enhancing glycemic control and mitigating the risk of complications from suboptimal diabetes management.
- Research suggests Tirzepatide may mitigate the likelihood of obesity-related complications.
- Scientists hypothesize Tirzepatide may ameliorate hepatic function and diminish hepatic steatosis in test subjects exhibiting nonalcoholic fatty liver disease (NAFLD) [iii].
- Tirzepatide has been suggested to exhibit a low propensity for inducing thyroid C cell tumors, a potential apprehension associated with certain other GLP-1 receptor agonists [iv].
A Comparative Analysis of Tirzepatide and Other Compounds
Tirzepatide Peptide vs. Semaglutide Peptide
Tirzepatide and Semaglutide are GLP-1 receptor agonists that have suggested noteworthy enhancements in glycemic control and reduced body weight among animal test subjects and in clinical trials with test subjects with type 2 diabetes mellitus.
Studies suggest Tirzepatide may have exhibited superior weight reduction outcomes compared to Semaglutide in preliminary laboratory investigations and researchers speculate that it may serve as a means of identifying and preventing glucose inbalances [v].
Tirzepatide Peptide vs. Liraglutide Peptide
Tirzepatide and Liraglutide are GLP-1 receptor agonists that have suggested efficacy in enhancing glycemic control and reducing weight. Nevertheless, research studies have suggested Tirzepatide may exhibit superior HbA1c and body weight reductions. Furthermore, Tirzepatide may exhibit more properties in models with renal dysfunction or cardiovascular ailments than Liraglutide.
In a randomized controlled Phase 3 clinical trial, Tirzepatide was suggested to be linked with a reduced incidence of hypoglycemia compared to Liraglutide. Additional research is required to comprehensively assess the effectiveness and potential of these two compounds in test subjects with said ailments.
Tirzepatide Peptide vs. Metformin Peptide
Studies suggest Metformin and Tirzepatide have potential to help regulate blood glucose levels, albeit through distinct mechanisms of action. Research suggests Metformin may exhibit hepatic gluconeogenesis inhibition, whereas Tirzepatide may act as a GLP-1 receptor agonist, augmenting insulin sensitivity and promoting insulin secretion.
Click here for more information about this research compound, but it is important to note that none of the compounds mentioned in this article are approved for human consumption. The above substances should only be procured and utilized by licensed professionals, scientists, or academics in confined laboratory settings.
References
[i] Farzam K, Patel P. Tirzepatide. [Updated 2022 Dec 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585056/
[ii] Juan P. Frias et al., Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes, The New England Journal of Medicine, August 5, 2021. N Engl J Med 2021; 385:503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
[iii] Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, Karanikas CA, Duffin KL, Robins DA, Haupt A. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care. 2020 Jun;43(6):1352-1355. doi: 10.2337/dc19-1892. Epub 2020 Apr 14. PMID: 32291277; PMCID: PMC7245348. https://pubmed.ncbi.nlm.nih.gov/32291277/
[iv] Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care. 2013 Aug;36 Suppl 2(Suppl 2):S245-52. doi: 10.2337/dcS13-2004. PMID: 23882053; PMCID: PMC3920789. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920789/
[v] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647. https://pubmed.ncbi.nlm.nih.gov/34170647/
